SWITCHED ON
The daily technology series nobody asked for but everyone needed
Smarter Than Natural: Cognitive Enhancement and the Line Between Treatment and Advantage
Surveys of university students at competitive institutions consistently find that a meaningful minority have used prescription stimulants without a prescription to study or work. This is not new. What is new is how normalised it has become, and how little serious public conversation has caught up with the scale of the practice.
We have always drawn a line between treating illness and enhancing normal function, and the line has always been more philosophically unstable than it appears. Cognitive enhancement drugs force the instability into the open, because the same molecule can be prescribed to treat a genuine attention disorder and taken, without prescription, by someone with no disorder at all who simply wants an edge.
Yesterday we covered the freshwater crisis — Cape Town's Day Zero near-miss, desalination's real economics, Singapore's NEWater as the success story in overcoming the "toilet to tap" perception problem, AI leak detection's underrated impact, and agricultural water pricing as the largest unrealised lever. Today we are shifting from planetary resource scarcity to something considerably more personal: the drugs and technologies people are using to enhance their own cognitive performance beyond what their unmedicated baseline would provide. Cognitive enhancement, sometimes called "smart drugs" or nootropics, sits at the genuinely difficult intersection of medicine, ethics, competition, and fairness that this episode is going to try to navigate honestly.
01 — What People Are Actually Taking
The most widely used cognitive enhancement substances are, somewhat unglamorously, drugs developed and approved for treating specific medical conditions, used off-label or without prescription by people who do not have those conditions. Methylphenidate (Ritalin) and amphetamine-based medications (Adderall), approved for treating attention deficit hyperactivity disorder, are the most extensively studied and most widely used stimulant cognitive enhancers, improving sustained attention and reducing the subjective experience of fatigue during extended cognitive work. Modafinil, approved for treating narcolepsy and other sleep disorders, has become popular among people without diagnosed sleep conditions specifically for its ability to maintain alertness and cognitive performance during extended wakefulness without the crash and dependency profile associated with traditional stimulants.
Surveys of university students, conducted across multiple countries and institutions, consistently find non-prescription stimulant use rates ranging from roughly five to twenty percent depending on the institution, country, and survey methodology, with rates typically higher at more academically competitive institutions and during high-stakes periods like final examinations. Similar patterns have been documented among surgeons, financial traders, and other professionals in high-stakes, high-cognitive-demand occupations, though workplace surveys are less extensive than the university-focused research literature.
The population using cognitive enhancement drugs without a prescription is not, primarily, people seeking a chemical shortcut to avoid work. It is disproportionately people already working extremely hard, in extremely competitive environments, seeking a marginal edge in contexts where marginal edges determine outcomes that matter enormously to their futures.
02 — What the Evidence Actually Shows About Efficacy
The scientific evidence for cognitive enhancement drugs' actual effectiveness in healthy, non-diagnosed individuals is more modest and more nuanced than the popular narrative — heavily shaped by cultural touchstones like the film Limitless — would suggest. Methylphenidate and amphetamines do reliably improve sustained attention and reduce the perception of fatigue during long cognitive tasks in healthy individuals, which is a genuine and measurable effect. What the evidence does not support is a general enhancement of intelligence, creativity, or complex problem-solving ability — the effects are concentrated in sustained attention and motivation rather than in raw cognitive capability, meaning the drugs help people work longer and with more focus on tasks they already know how to do, rather than making them capable of qualitatively better thinking.
A comprehensive 2015 review in the journal Nature examining the evidence for cognitive enhancers found that the effects were generally modest, highly task-dependent, and often smaller than users' subjective sense of enhancement suggested — a discrepancy that researchers attribute partly to the drugs' mood-elevating effects, which can make users feel more confident and productive without a correspondingly large objective improvement in output quality. This is an important nuance: some of the perceived benefit of cognitive enhancement drugs may be a subjective sense of enhanced performance that exceeds the objectively measurable improvement, which has implications for how we should think about their fairness in competitive contexts.
03 — The Fairness Question in Competitive Environments
The most serious ethical concern raised by cognitive enhancement is structural rather than individual: if a meaningful proportion of students or professionals in a competitive environment are using cognitive enhancers, does this create pressure on everyone else to use them too, simply to remain competitive, regardless of their personal views on the practice? This dynamic — sometimes called a coercive arms race — has clear parallels to the doping debates in competitive sports that have occupied international sporting bodies for decades, with one crucial difference: unlike sports, most academic and professional cognitive competitions have no testing regime, no banned substances list, and no enforcement mechanism at all.
The access and equity dimension compounds this concern significantly. Obtaining a prescription for methylphenidate or modafinil, whether legitimately for a diagnosed condition or through the grey-market channels by which many non-prescribed users obtain them, requires financial resources, healthcare access, and social capital that are not equally distributed. If cognitive enhancement provides even a modest competitive edge in high-stakes academic and professional competition, and access to that edge correlates with existing socioeconomic advantage, cognitive enhancement risks becoming another mechanism through which existing inequality compounds rather than a genuinely accessible tool for individual improvement.
04 — The Treatment-Enhancement Distinction and Why It Is Harder Than It Looks
The conventional ethical framework for thinking about medical intervention distinguishes between treatment — restoring a person to normal function from a diagnosed deficit — and enhancement — improving function beyond what would be considered normal or healthy. This distinction has intuitive appeal and underlies much of medical ethics and health insurance policy. It is also considerably less stable than it initially appears, for reasons that cognitive enhancement drugs expose with particular clarity.
Attention deficit hyperactivity disorder is diagnosed along a spectrum, and the diagnostic threshold — where "distractible" becomes "disordered" — involves clinical judgment applied to a continuous trait distribution rather than a clean binary category that nature provides. A person just below the diagnostic threshold, taking the same medication as a person just above it, is engaging in what looks structurally identical to the person above the threshold, despite one being classified as "treatment" and the other as "enhancement." This is not a hypothetical philosophical puzzle — ADHD diagnosis rates have increased substantially over recent decades, partly reflecting genuine improved recognition of a previously underdiagnosed condition, and partly reflecting, some researchers argue, a lowering of diagnostic thresholds that blurs the treatment-enhancement line in practice.
This does not mean the treatment-enhancement distinction is meaningless — treating a genuine, functionally impairing attention disorder is categorically different in its ethical status from a high-achieving student without such a disorder seeking a competitive edge, even if the pharmacological mechanism is identical. It means the distinction requires more careful, case-by-case clinical and ethical judgment than a simple bright-line rule can provide, and that policy responses built around a clean treatment-enhancement binary will struggle with the genuinely blurry cases that exist in large numbers at the boundary.
05 — What a Sensible Policy Response Looks Like
The current policy environment for cognitive enhancement drugs is largely a legacy of drug scheduling decisions made for reasons unrelated to their use as cognitive enhancers, applied inconsistently, with minimal serious engagement with the enhancement use case that a significant fraction of actual consumption represents. This is not a satisfactory state of affairs, and several more thoughtful responses deserve consideration even though none has been adopted at scale.
Honest public health communication about the actual, modest, task-specific nature of the cognitive benefits — rather than either moral panic or tacit endorsement of exaggerated claims — would help students and professionals make more informed decisions about a practice that is happening regardless of official disapproval. Reducing the coercive pressure that drives non-medical use in the first place — addressing the extreme competitive intensity of academic and professional environments that makes marginal cognitive edges feel necessary rather than optional — is a more fundamental intervention than drug policy alone, though it requires cultural and institutional change that is considerably harder to implement than any pharmaceutical regulation. And genuine research investment into understanding the long-term effects of sustained non-medical stimulant use, which remains surprisingly under-studied given how widespread the practice has become, would allow the individuals making these choices to do so with better information than currently exists.
The honest conclusion is that cognitive enhancement drug use is already a significant and largely unaddressed phenomenon in competitive academic and professional environments, that the ethical and policy frameworks available to think about it are not well suited to its genuinely blurry treatment-enhancement boundary, and that the coercive competitive dynamics that drive much of the practice are a more tractable and more important intervention point than drug scheduling debates that have occupied most of the limited policy attention this issue has received.
Tomorrow we are going somewhere considerably more concrete — the technology of space debris and the increasingly urgent problem of keeping Earth's orbit usable, connecting back to our Season One episode on satellite constellations and extending into what happens if we do not solve it in time. See you then.
Switched On is a daily technology series covering the ideas, systems, and arguments shaping the digital world. Opinionated. Witty. Occasionally wrong. Always worth the argument.
